Compare Organon & Co. Common Stock (OGN) vs iShares Silver Trust (SLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs iShares Silver Trust — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while iShares Silver Trust trades at $51.18 (market cap $29.73B). The key difference: iShares Silver Trust is far larger — about 8.2× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while iShares Silver Trust pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and iShares Silver Trust for 90 Days on average.
| OGN | SLV | |
|---|---|---|
Market Cap | $3.62B | $29.73B |
Volume | 2,892,999 | 17,545,887 |
Sector | Health | — |
52-Week High | $13.81 | $105.57 |
52-Week Low | $5.70 | $42.40 |
Typical Hold Time | 0 Days | 90 Days |
Enterprise Value | $11.04B | — |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
SLV, the iShares Silver Trust ETF, is trading at $50.22, down 7.6% over 24 hours amid a bearish technical signal. The trust holds substantial assets of $13.41 billion with minimal liabilities, but financial metrics like P/E and revenue are unavailable. Recent news highlights pressure from rising Treasury yields and a stronger dollar, contributing to silver's sharp decline.
The outlook remains cautious due to macroeconomic headwinds and Fed policy uncertainty. While silver's industrial and monetary appeal offers long-term potential, near-term volatility and bearish technical indicators suggest limited upside. Risks include interest rate sensitivity and market sentiment shifts, requiring careful monitoring for entry points.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About iShares Silver Trust
The ETF seeks to reflect such performance before payment of the ETF's expenses and liabilities. It is not actively managed. The ETF does not engage in any activities designed to obtain a profit from, or to ameliorate losses caused by, changes in the price of silver.
Read more on SLV →
